Compare Pfizer Inc (PFE) vs Quantum Computing Inc (QUBT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Quantum Computing Inc — how do they compare? Pfizer Inc trades at $28.13 (market cap $158.56B), while Quantum Computing Inc trades at $7.38 (market cap $1.69B). The key difference: Pfizer Inc is far larger — about 93.8× Quantum Computing Inc's market cap, and Pfizer Inc pays a 6.18% dividend while Quantum Computing Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Quantum Computing Inc for 25 Days on average.
| PFE | QUBT | |
|---|---|---|
Market Cap | $158.56B | $1.69B |
Volume | 44,138,282 | 7,991,522 |
Sector | Health | Technology |
52-Week High | $29.02 | $21.78 |
52-Week Low | $23.67 | $6.31 |
Typical Hold Time | 158 Days | 25 Days |
Enterprise Value | $210.06B | $753.24M |
Dividend Yield | 6.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Quantum Computing Inc. (QUBT) trades at $7.62, down 3.05% today, with a bearish technical signal despite bullish oscillators. The company shows explosive revenue growth from $682K in 2025 to $10M in 2026 but remains deeply unprofitable with a -152.45% net income margin. Recent developments include the Dirac-3S quantum system announcement and a $42.5M backlog, though rising expenses and cash burn persist.
Analysts maintain a bullish consensus with a $17.33 price target (75% buy ratings), seeing potential in QUBT's quantum technology expansion. However, significant execution risks, continued losses, and high valuation (P/S 157.36) create substantial downside potential if commercialization timelines slip or funding needs increase.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →
